Bristol Myers Squibb (BMY) Other Non-Current Liabilities (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Other Non-Current Liabilities for 18 consecutive years, with $4.3 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other Non-Current Liabilities fell 12.16% year-over-year to $4.3 billion in Q2 2026; TTM through Jun 2026 was $4.3 billion, a 12.16% decrease from a year earlier, with the FY2025 full-year figure at $5.0 billion, up 12.84% from the prior year.
• Other Non-Current Liabilities was $4.3 billion for Q2 2026 at Bristol Myers Squibb, down from $4.9 billion in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $7.3 billion in Q1 2022 and troughed at $4.3 billion in Q2 2026.
• A 5-year average of $5.7 billion and a median of $5.7 billion in 2023 frame the typical range for Other Non-Current Liabilities.
• The widest YoY moves for Other Non-Current Liabilities: up 15.46% in 2025, down 33.5% in 2025.
• Over 5 years, Other Non-Current Liabilities stood at $6.6 billion in 2022, then decreased by 2.56% to $6.4 billion in 2023, then sank by 30.4% to $4.5 billion in 2024, then grew by 12.84% to $5.0 billion in 2025, then fell by 13.92% to $4.3 billion in 2026.
• The last three Other Non-Current Liabilities figures came in at $4.3 billion (Q2 2026), $4.9 billion (Q1 2026), and $5.0 billion (Q4 2025), per Business Quant data.